NEW ORLEANS — Young people with type 2 diabetes taking the once-weekly GLP-1 receptor agonist dulaglutide had a decrease in HbA1c at 26 weeks without a significant change in BMI, according to findings from a phase 3 trial.
“This is a breakthrough in the management of youth type 2 diabetes,” Silva Arslanian, MD, the Richard L. Day professor of pediatrics in the department of pediatric endocrinology, metabolism and diabetes at the University of Pittsburgh School of Medicine, director of the Pediatric Clinical and Translational Research Center, and scientific director for the